Atopic dermatitis: A global health perspective
- PMID: 38151270
- DOI: 10.1111/jdv.19723
Atopic dermatitis: A global health perspective
Abstract
The International Society of AD (ISAD) organized a roundtable on global aspects of AD at the WCD 2023 in Singapore. According to the Global Burden of Disease (GBD) consortium, at least 171 million individuals were affected with AD in 2019, corresponding to 2.23% of the world population, with age-standardized prevalence and incidence rates that were relatively stable from 1990 to 2019. Based on the panel experience, most AD cases are mild-to-moderate. Without parallel data on disease prevalence and severity, the GBD data are difficult to interpret in many regions. This gap is particularly important in countries with limited medical infrastructure, but indirect evidence suggests a significant burden of AD in low-and-medium resource settings, especially urban areas. The Singapore roundtable was an opportunity to compare experiences in World Bank category 1 (Madagascar and Mali), 3 (Brazil, China) and 4 (Australia, Germany, Qatar, USA, Singapore, Japan) countries. The panel concluded that current AD guidelines are not adapted for low resource settings and a more pragmatic approach, as developed by WHO for skin NTDs, would be advisable for minimal access to moisturizers and topical corticosteroids. The panel also recommended prioritizing prevention studies, regardless of the level of existing resources. For disease long-term control in World Bank category 3 and most category 4 countries, the main problem is not access to drugs for most mild-to-moderate cases, but rather poor compliance due to insufficient time at visits. Collaboration with WHO, patient advocacy groups and industry may promote global change, improve capacity training and fight current inequalities. Finally, optimizing management of AD and its comorbidities needs more action at the primary care level, because reaching specialist care is merely aspirational in most settings. Primary care empowerment with store and forward telemedicine and algorithms based on augmented intelligence is a future goal.
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Similar articles
-
Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.Lancet Respir Med. 2025 May;13(5):425-446. doi: 10.1016/S2213-2600(25)00003-7. Epub 2025 Mar 24. Lancet Respir Med. 2025. PMID: 40147466
-
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017.Br J Dermatol. 2021 Feb;184(2):304-309. doi: 10.1111/bjd.19580. Epub 2020 Nov 29. Br J Dermatol. 2021. PMID: 33006135
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
Patients' and Caregivers' Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries.J Allergy Clin Immunol Pract. 2023 Jan;11(1):264-273.e1. doi: 10.1016/j.jaip.2022.10.032. Epub 2022 Nov 2. J Allergy Clin Immunol Pract. 2023. PMID: 36332836
-
Global, regional, and national burden of older adult atopic dermatitis in 204 countries and territories worldwide.Front Public Health. 2025 Apr 2;13:1569119. doi: 10.3389/fpubh.2025.1569119. eCollection 2025. Front Public Health. 2025. PMID: 40241972 Free PMC article.
Cited by
-
The therapeutic effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on chemically induced atopic dermatitis.Sci Rep. 2024 Oct 8;14(1):23402. doi: 10.1038/s41598-024-73951-2. Sci Rep. 2024. PMID: 39379428 Free PMC article.
-
Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch.Dermatol Ther (Heidelb). 2024 Jun;14(6):1561-1573. doi: 10.1007/s13555-024-01171-7. Epub 2024 May 22. Dermatol Ther (Heidelb). 2024. PMID: 38777937 Free PMC article.
-
Dermatologists' Perceptions and Factors Influencing the Selection of Topical Anti-Inflammatory Agents for Atopic Dermatitis in China: A Cross-Sectional Survey Study.Clin Cosmet Investig Dermatol. 2024 Nov 28;17:2713-2723. doi: 10.2147/CCID.S487996. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 39624065 Free PMC article.
-
Advancements in artificial intelligence for atopic dermatitis: diagnosis, treatment, and patient management.Ann Med. 2025 Dec;57(1):2484665. doi: 10.1080/07853890.2025.2484665. Epub 2025 Apr 8. Ann Med. 2025. PMID: 40200717 Free PMC article. Review.
-
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial.JAMA Dermatol. 2025 Jul 1;161(7):688-697. doi: 10.1001/jamadermatol.2025.0982. JAMA Dermatol. 2025. PMID: 40305055 Clinical Trial.
References
REFERENCES
-
- Wallach D, Tilles G. Le premier congrès international de dermatologie et de syphiligraphie Paris, 5–10 août 1889 [cited 2023 July 22]. Available from: https://www.biusante.parisdescartes.fr/sfhm/hsm/HSMx1990x024x002/HSMx199...
-
- Morris M. Special discussion on prurigo, lichenification and allied conditions. Br J Dermatol. 1912;24:245–267.
-
- Williams HC, Strachan DP, Hay RJ. Childhood eczema: disease of the advantaged? BMJ. 1994;308:1132–1135.
-
- Schmid‐Grendelmeier P, Takaoka R, Ahogo KC, Belachew WA, Brown SJ, Correia JC, et al. Position statement on atopic dermatitis in sub‐Saharan Africa: current status and roadmap. J Eur Acad Dermatol Venereol. 2019;33:2019–2028.
-
- Lopez Carrera YI, Al Hammadi A, Huang YH, Llamado LJ, Mahgoub E, Tallman AM. Epidemiology, diagnosis, and treatment of atopic dermatitis in the developing countries of Asia, Africa, Latin America, and the Middle East: a review. Dermatol Ther. 2019;9:685–705.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous